Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Lenacapavir (LEN), a first in class capsid inhibitor approved by the FDA (22DEC2022) as a twice yearly long-acting injectable used with an optimized background regimen (OBR), is indicated for heavily treatment-experienced individuals with multidrug resistant HIV-1 infection who are failing their current antiretroviral therapy (ART) regimen due to resistance, intolerance, or safety concerns. We…
Background COVID-19 remains a public health concern despite availability of effective interventions. Clinical studies have shown that remdesivir (RDV) reduces mortality, hospitalization, disease progression, and recovery time in individuals hospitalized with COVID-19. Current NIH guidelines recommend RDV treatment for patients at high risk of disease progression. This study of patients hospitalized for COVID-19 aimed to…
Background Dolutegravir (DTG) is a widely used effective integrase strand transfer inhibitor with a high barrier to resistance. It is a recommended first-line treatment regimen for HIV-1-infected adults and children. However, DTG’s impact is limited by its daily dose requirements and suboptimal adherence. Long-acting formulations would improve optimal usage and reduce the emergence of drug…
Background The association of intramuscularly administered Long-acting cabotegravir and rilpivirine (LA CAB+RPV) has been proven to be effective and safe in the maintenance treatment of people with HIV (PWH). The study aimed to assess LA CAB+RPV efficacy and safety in Older PWH (OPWH). Methods PWH in the GEPPO cohort (age >65 years) who started LA CAB+RPV…
Background It is estimated that there are over 1.2 million people with HIV (PWH) in the United States. Of these, ~1% are heavily treatment-experienced (HTE) with multidrug resistant (MDR) HIV infection. MDR HIV is found most often in PWH with extensive prior exposure to antiretrovirals (ARVs). For these underrepresented HTE patients with MDR HIV-1, it…
Background This study aimed to focus on sex-based characteristics, patient reported outcomes (PROs) and effectiveness in people with HIV switching to long-acting cabotegravir-rilpivirine (LA-CAB/RPV) administered Q2M in Hospital Clínic of Barcelona, Spain. Methods People starting LA-CAB/RPV were invited to participate in an observational, prospective study approved by the local Ethical Committee. Clinical information was routinely…
Background Dual nucleos(t)ide reverse transcriptase inhibitor (NRTI)-free regimens are an attractive choice for simplification of antiretroviral therapy (ART) in treatment-experienced patients. Fixed-dose formulation of rilpivirine (RPV) plus dolutegravir (DTG) is recommended for ART optimization, while Doravirine (DOR) plus DTG is a more recent NRTI-free option. We aimed to compare virologic suppression (VS) in treatment-experienced persons…
Background In treatment-naïve adults with HIV-1 and hepatitis B virus (HBV) co-infection, the ALLIANCE study showed that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was noninferior for HIV-1 RNA suppression and superior for HBV DNA suppression compared to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) at Week [W] 48. Suppression rates were maintained through W96, after which DTG+F/TDF participants switched to…
Background Adherence to antiretroviral therapy (ART) is independently associated with viral load (VL) suppression among people living with HIV (PLHIV). Previous studies have demonstrated that dolutegravir-based regimens (DBR) have forgiveness for strict adherence to achieve VL suppression (VLS) as measured by pharmacy refill and electronic drug monitoring, where 75% and 80% adherence, respectively, can achieve…
Background Antiretroviral options for older adults are limited by age-related co-morbidities and drug toxicities. We evaluated whether a first line switch strategy in older adults maintains viral suppression while minimizing contribution to comorbidities. Methods The bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)-elderly study was an open-label, randomized, non-inferiority trial conducted at two sites in Kenya. HIV-1 positive adults ≥60…